P/E at 29.6 vs Industry's 37.2: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry P/E

The stock’s P/E ratio of 29.61 represents a discount of approximately 20.4% relative to the sector average of 37.19. This valuation gap suggests that the market is pricing in either a more cautious outlook on Dr Reddys Laboratories Ltd or recognising sector-wide premium valuations that the company does not command. Such a discount can reflect concerns over growth prospects, profitability, or risk factors specific to the company. However, it also raises the question of whether the stock is undervalued relative to its peers — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating?

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a pronounced divergence in momentum. Over the past year, Dr Reddys Laboratories Ltd has declined by 11.24%, underperforming the Sensex’s 4.68% loss. The underperformance intensifies over shorter intervals: the three-month return stands at -13.34% versus the Sensex’s modest 0.98% gain, while the one-month return is a steep -15.51% compared to the Sensex’s 1.56% rise. Even the one-week performance is negative at -1.72%, contrasting with the Sensex’s 1.67% advance. This pattern indicates a recent acceleration in selling pressure, which contrasts with the broader market’s modest gains — is this a temporary setback or a sign of deeper weakness?

Moving Average Configuration: Bearish Technical Setup

The technical picture for Dr Reddys Laboratories Ltd remains firmly bearish. The stock is trading below all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This alignment indicates sustained downward momentum without signs of a near-term recovery. Being below the short-term averages suggests immediate selling pressure, while the position below the long-term averages confirms a persistent downtrend. The absence of any bounce above these levels raises questions about the stock’s ability to regain investor confidence in the near term — is this a genuine recovery or a dead-cat bounce?

Relative Performance vs Sensex: Consistent Underperformance

Over longer horizons, Dr Reddys Laboratories Ltd has consistently lagged the Sensex. The three-year return is 2.59%, significantly below the Sensex’s 17.39%. Similarly, the five-year return of 21.63% trails the Sensex’s 47.70%, and the ten-year return of 95.16% is well short of the Sensex’s 176.87%. This persistent underperformance highlights challenges in delivering market-beating returns over extended periods. The stock’s recent short-term weakness compounds this trend, suggesting that the company has struggled to regain momentum — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Sector Performance Context: Mostly Positive Results

The Pharmaceuticals & Biotechnology sector has seen a generally positive earnings season so far, with six companies reporting results: four posted positive outcomes and two were flat, with no negative surprises. This sector-wide resilience contrasts with the underwhelming performance of Dr Reddys Laboratories Ltd, which has not capitalised on the broader sector momentum. The stock’s mid-cap market capitalisation of ₹95,691.41 crores places it in a competitive position, yet its relative weakness raises questions about company-specific factors influencing investor sentiment — what is the current rating for this mid-cap stock?

Rating Reassessment: From Hold to a New Status

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold to a different status, reflecting a reassessment of its fundamentals and market position. The previous Mojo Score was 36.0, and the current rating adjustment aligns with the observed valuation discount and recent performance trends. This change underscores the evolving view on the stock’s prospects amid a challenging market environment and technical weakness — how does this rating update affect the stock’s outlook?

Conclusion: A Complex Picture Emerging from the Data

The data on Dr Reddys Laboratories Ltd paints a nuanced picture. The stock trades at a meaningful discount to its sector’s P/E ratio, signalling market caution or undervaluation. Its performance across timeframes reveals accelerating weakness in recent months, with returns significantly lagging the Sensex and sector peers. The technical setup remains bearish, with the stock below all major moving averages, indicating persistent downward momentum. Despite a generally positive sector earnings environment, the company’s relative underperformance and recent rating reassessment highlight challenges that investors must weigh carefully — should investors reconsider their position in Dr Reddys Laboratories Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →